The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.

The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.

The test is designed to identify various obesity phenotypes that doctors can use to personalize treatment plans.

Academic researchers' efforts to advance CAR T-cell immunotherapy research in this partnership recently received a boost from PICI.

The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.

The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Wednesday recommended Genentech's ALK inhibitor Alecensa (alectinib) as an adjuvant therapy option for certain ...

Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...